RE: RE: Coverage initiated by LifeSci Advisors I think your right Fairweather, I remember back when Adherex was going to partner for their ADH1 compound they used a company to help find them partners.
At that time large pharma was not very receptive to partnerships. They were still able to get a decent offer, which was rejected by management. (I am still a little bitter about that)
Do you think they may be using a company to help with partnership negotiations now?
I really feel like a no brainer partnership is GSK.
GSK will be getting milestone payments and double digit royalties on Eniluricil as it progresses. Since they have such a vested interest you figure it would make sense for them to take the lead.
$400 million of sales( number from the new report for potential market size) at a multiple of 3 would be market cap of $1,2 billion. Lets say that will be in 5 years discount to today using 10% gives a present value of $750 million.
use half of that value to be conservative. $375 million should be todays market cap.
with 25 million shares out that is $15.00 per share.
There is lots of room for the stock to go from here.